Rafael Holdings Inc

Rafael Holdings insider sale: CEO Jonas Howard sells 9,826 Class B shares at $1.50—steady liquidity moves amid Phase 3 trial and Cyclo Therapeutics integration.

Insider buying of Rafael Holdings’ Class B shares signals optimism, but negative earnings and a low market cap mean investors should watch for dilution and future funding needs.

Executive insider buy of Rafael Holdings shares signals long‑term confidence in the company’s late‑stage oncology pipeline and real‑estate strategy, hinting at future upside.